Connection
Bradley Corr to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Bradley Corr has written about Programmed Cell Death 1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.050 |
|
|
|
-
Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A, Stebbing J, Joshi B, Bourdelais S, Delepine C, Chand D, Wu W, Johnson B, Grossman JE, O'Day SJ, Matulonis UA, Gordon MS. Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer. 2025 Dec 23; 13(12).
Score: 0.050